+
+
Stay Informed
TAVI

NAVITOR™ WITH FLEXNAV™ TAVI SYSTEM CLINICAL DATA

Smart Sealing. Exceptional Stability. Uncompromised Access.

EXCELLENT OUTCOMES
IN CLINICAL TRIAL RESULTS

 

30-DAY1

0%

MODERATE OR
SEVERE PVL

0%

ALL CAUSE
MORTALITY

0.8%

DISABLING
STROKE

0.8%

MAJOR VASCULAR
COMPLICATIONS

7.4mmHg

MEAN
GRADIENT

1-YEAR1

1.0%

MODERATE PVL
(0% SEVERE PVL)

4.2%

ALL CAUSE
MORTALITY

0.8%

DISABLING
STROKE

0.8%

MAJOR VASCULAR
COMPLICATIONS

7.5mmHg

MEAN
GRADIENT

  • CLINICAL OUTCOMES

    30-DAY

    30-DAYNAVITOR™1
    N=120    		EVOLUT‡ PRO2
    N=60    		ACURATE NEO2‡3
    N=120    		SAPIEN‡ 34
    N=96*
    All-Cause Mortality0.0%1.7%3.3%2.1%
    Disabling Stroke0.8%1.7%1.7%0.0%
    Life-Threatening Bleeding2.5%11.7%5.0%3.1%
    Acute Kidney Injury Stage 2/31.7%1.7%0.8%1.0%
    Major Vascular Complications0.8%††10.0%3.3%4.2%
    New Permanent Pacemaker
    Implantation    		15.0%11.8%16.1%14.5%

     

    1-YEAR

    1-YEARNAVITOR™1
    N=120    		EVOLUT‡ PRO5
    N=60    		ACURATE NEO2‡3
    N=120    		SAPIEN‡ 36
    N=96*
    All-Cause Mortality4.2%11.8%11.9%8.4%
    Disabling Stroke0.8%1.7%1.7%1.1%
    Life-Threatening Bleeding5.0%NR8.5%NR
    Acute Kidney Injury Stage 2/31.7%NR0.8%NR
    Major Vascular Complications0.8%NR3.3%NR
    Naive Pacemaker Implantation16.8%**15.9%18.8%15.7%

    NOTE: Data not from head-to-head studies. Data provided for informational purposes only.

    NOTE: Reference data reflects results from prospective, multicenter clinical studies with contemporary valves in high- and extreme-risk surgical patients conducted in support of CE Mark approval (except Sapien‡ 3 study cohort includes mixed high and intermediate risk patients).

    †† CEC adjudicated as related to procedure but not to device.

    * Transfemoral access cohort.

    ** Of the 18 subjects who required new PPI through 1 year, 13 had pre-existing conduction abnormalities.

  • SMART SEALING

    30-DAY

    PVL 30-DAY
    ECHO CORE
    LAB DATA    		NAVITOR™1
    N=118    		EVOLUT‡ PRO2
    N=58    		ACURATE NEO2‡3
    N=100

    SAPIEN‡ 34

    N=113*

    None/Trace79.7%72.4%35.0%74.3%
    Mild20.3%27.6%62.0%22.1%
    Moderate0.0%0.0%3.0%3.5%
    Severe0.0%0.0%0.0%0.0%

     

    1-YEAR

    PVL 1-YEAR
    ECHO CORE
    LAB DATA    		NAVITOR™1
    N=104    		EVOLUT‡ PRO5
    N=46    		ACURATE NEO2‡3
    N=81

    SAPIEN‡ 36

    N=100*

    None/Trace70.2%89.1%60.5%84.0%
    Mild28.8%10.9%37.0%14.0%
    Moderate1.0%0.0%2.5%2.0%
    Severe0.0%0.0%0.0%0.0%

    Based on number of subjects with data evaluable by the echo core lab.

    NOTE: Data not from head-to-head studies. Data provided for informational purposes only.

    NOTE: Reference data reflects results from prospective, multicenter clinical studies with contemporary valves in high- and extreme-risk surgical patients conducted in support of CE Mark approval (except Sapien‡ 3 study cohort includes mixed high and intermediate risk patients).

    * Includes data on subjects implanted via transapical and transaortic access.

  • EXCEPTIONAL HEMODYNAMICS

    30-DAY

    30-DAY
    ECHO CORE
    LAB DATA

    NAVITOR™1

     

    		EVOLUT‡ PRO2
         		ACURATE NEO2‡3
     

    SAPIEN‡ 34

     

    Mean Gradient (mmHg)7.4
    (N=118)    		6.4
    (N=55)    		7.9
    (N=104)    		10.6
    (N=119*)
    EOA (cm2)2.0
    (N=101)    		2.0
    (N=47)    		1.7
    (N=99)    		1.5
    (N=97*)

     

    1-YEAR

    1-YEAR
    ECHO CORE
    LAB DATA

    NAVITOR™5

     

    		EVOLUT‡ PRO5
         		ACURATE NEO2‡3
     

    SAPIEN‡ 36

     

    Mean Gradient (mmHg)7.5
    (N=107)    		7.1
    (N=44)    		7.6
    (N=85)    		10.9†
    (N=86)
    EOA (cm2)1.9
    (N=88)    		2.0
    (N=40)    		1.7
    (N=77)    		1.5†
    (N=64)

    Based on number of subjects with data evaluable by the echo core lab.

    NOTE: Data not from head-to-head studies. Data provided for informational purposes only.

    NOTE: Reference data reflects results from prospective, multicenter clinical studies with contemporary valves in high- and extreme-risk surgical patients conducted in support of CE Mark approval (except Sapien‡ 3 study cohort includes mixed high and intermediate risk patients).

    * Includes data on subjects implanted via transapical and transaortic access.

    † Paired Analysis

‡ Indicates a third-party trademark, which is property of its respective owner.

MAT-2105703 v3.0 | Item approved for OUS use only.

References
  1. Smith, D. One-year clinical trial results with a next-generation aortic transcatheter heart valve. Presented at: EuroPCR conference; May 17-20, 2022.
  2. Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap.
    J Am Coll Cardiol Intv. 2018;11:160-168.
  3. Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol. 2021 Dec;110(12):1912-1920.
  4. Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64:2235-43.
  5. Wyler von Ballmoos MC, Reardon MJ, Williams MR, et al. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovasc Revasc Med. 2021 May;26:12-16.
  6. Webb, J. 1-year outcomes from the Sapien 3 Trial. Presented at: EuroPCR conference; May 19-22, 2015.
Abbott Logo

Follow Abbott

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v17.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+